Dyadic International Inc (DYAI NASDAQ) stock market data APIs
$0.942
0.01(1.1%)
as of July 3, 2025
Try our APIs with
free plan!
Dyadic International Inc Financial Data Overview
Price chart is built with
Anychart
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Prev. Close
0.942
Open
0.9522
High
0.9813
Low
0.9103
52 wk Range
0.912-2.2
Market Cap
28 285 K
Shares Outstanding
30 091 K
Revenue
3 554 K
EPS
-0.0678
Beta
0.9
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dyadic International Inc data using free add-ons & libraries
Get Dyadic International Inc Fundamental Data
Dyadic International Inc Fundamental data includes:
- Net Revenue: 3 554 K
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dyadic International Inc News
New
Dyadic rebrands as Applied BioSolutions to focus on commercial growth
JUPITER, Fla. - Dyadic International, Inc. (NASDAQ:DYAI) announced Wednesday it will begin operating under the name Dyadic Applied BioSolutions in 30 days, signaling a strategic shift from research to...
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyad...
Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the ...
Dyadic to Present at World Vaccine Congress | Washington
JUPITER, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company that utilizes...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
